Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer

Table 1

(a) Relationship between clinicopathological parameters and mRNA expression levels of uPA system members in tumor tissues of PCa patients (𝑛=132). (b) Relationship between clinicopathological parameters and antigen levels of uPA system members in the serum of PCa patients (𝑛=81).

(a)

Clinicopathological parameters	Number of cases	uPA low/high	uPAR low/high	PAI-1 low/high
	132
Age		𝑃=0.602	𝑃=1.000	𝑃=0.602
<65 yrs	66	35/31	33/33	35/31
≥65 yrs	66	31/35	33/33	31/35
Lymph node status*		𝑃=0.796	𝑃=0.795	𝑃=0.434
pN0	107	56/51	57/50	58/49
pN1	17	8/9	8/9	7/10
Tumor stage		𝑃=0.081	𝑃=0.296	𝑃=0.163
pT2	69	40/29	38/31	39/30
pT3 + 4	63	26/37	28/35	27/36
Gleason score		𝐏=𝟎.𝟎𝟎𝟏	𝑃=0.199	𝑃=0.007
GS < 7	35	19/16	21/14	17/18
GS = 7	56	36/20	28/28	36/20
GS > 7	41	11/30	17/24	13/28

Statistical analysis was performed using Fisher’s exact test. Significant value is marked in bold. The Bonferroni-adjusted threshold for significance is at 𝛼=0.0042.
∗Number of patients 𝑛=124.

(b)

Clinicopathological parameters	Number of cases	uPA low/high	uPAR low/high	PAI-1 low/high
	81
Age		𝑃=0.025	𝑃=0.377	𝑃=0.508
<65 yrs	40	25/14	23/17	22/18
≥65 yrs	41	15/26	19/22	19/22
Lymph node status*		𝑃=0.311	𝑃=0.5185	𝑃=0.311
pN0	69	36/33	36/33	33/36
pN1	10	3/7	4/6	7/3
Tumor stage		𝑃=0.263	𝑃=0.508	𝑃=0.825
pT2	43	24/19	24/19	21/22
pT3 + 4	38	16/22	18/20	19/19
Gleason score		𝑃=0.159	𝑃=0.838	𝑃=0.429
GS < 7	18	7/11	9/9	8/10
GS = 7	42	25/17	23/19	19/23
GS > 7	21	8/13	10/11	13/8

Statistical analysis was performed using Fisher’s exact test. The Bonferroni-adjusted threshold for significance is at 𝛼=0.0042.
∗Number of patients 𝑛=79.